Rohto Pharmaceutical Co.,Ltd.
Symbol: 4527.T
JPX
3200
JPYDzisiejsza cena rynkowa
23.2296
Wskaźnik P/E
0.8870
Wskaźnik PEG
730.04B
Kapitalizacja MRK
- 0.01%
Rentowność DIV
Rohto Pharmaceutical Co.,Ltd. (4527-T) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 79951 | 72791 | 52964 | ||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 1008 | 661 | -1199 | ||||||||||||||||
balance-sheet.row.net-receivables | 0 | 60656 | 51682 | 47865 | ||||||||||||||||
balance-sheet.row.inventory | 0 | 41062 | 33527 | 27925 | ||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 29547 | 24678 | 20975 | ||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 190246 | 164306 | 133071 | ||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 66182 | 62839 | 49790 | ||||||||||||||||
balance-sheet.row.goodwill | 0 | 2564 | 2954 | 4014 | ||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 6997 | 6338 | 3521 | ||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 9561 | 9292 | 7535 | ||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 32629 | 27471 | 27425 | ||||||||||||||||
balance-sheet.row.tax-assets | 0 | 5371 | 5297 | 4606 | ||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 5686 | 5419 | 3361 | ||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 119429 | 110318 | 92717 | ||||||||||||||||
balance-sheet.row.other-assets | 0 | 2 | 3 | 2 | ||||||||||||||||
balance-sheet.row.total-assets | 0 | 309677 | 274627 | 225790 | ||||||||||||||||
balance-sheet.row.account-payables | 0 | 16025 | 13660 | 9603 | ||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 4177 | 8033 | 2312 | ||||||||||||||||
balance-sheet.row.tax-payables | 0 | 6230 | 3185 | 6138 | ||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 7516 | 13350 | 5787 | ||||||||||||||||
Deferred Revenue Non Current | 0 | 3146 | 3387 | 5126 | ||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 29368 | 27256 | 10008 | ||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 14439 | 19311 | 12708 | ||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 1184 | 1184 | 179 | ||||||||||||||||
balance-sheet.row.total-liab | 0 | 94601 | 90799 | 69179 | ||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.common-stock | 0 | 6504 | 6504 | 6504 | ||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 184005 | 162195 | 145511 | ||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 18705 | 8735 | 3167 | ||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 354 | 851 | 725 | ||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 209568 | 178285 | 155907 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 309677 | 274627 | 225790 | ||||||||||||||||
balance-sheet.row.minority-interest | 0 | 5508 | 5543 | 704 | ||||||||||||||||
balance-sheet.row.total-equity | 0 | 215076 | 183828 | 156611 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||
Total Investments | 0 | 33637 | 28132 | 26226 | ||||||||||||||||
balance-sheet.row.total-debt | 0 | 11693 | 21383 | 8099 | ||||||||||||||||
balance-sheet.row.net-debt | 0 | -68258 | -51408 | -44865 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 34290 | 27953 | 23006 | ||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 7801 | 7673 | 6748 | ||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -11277 | 458 | 3402 | ||||||||||||||||
cash-flows.row.account-receivables | 0 | -7560 | -30 | 2464 | ||||||||||||||||
cash-flows.row.inventory | 0 | -6105 | -3061 | 3188 | ||||||||||||||||
cash-flows.row.account-payables | 0 | 1716 | 3323 | -2811 | ||||||||||||||||
cash-flows.row.other-working-capital | 0 | 672 | 226 | 561 | ||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 110 | -8834 | -13148 | ||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -9908 | -11328 | -10304 | ||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -1582 | -1203 | -1516 | ||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -5940 | -5615 | -2206 | ||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 2641 | 1963 | 4050 | ||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 1613 | -223 | -261 | ||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -13176 | -16406 | -10237 | ||||||||||||||||
cash-flows.row.debt-repayment | 0 | -8761 | -3133 | -1880 | ||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.dividends-paid | 0 | -4676 | -3422 | -2965 | ||||||||||||||||
cash-flows.row.other-financing-activites | 0 | -2762 | 10025 | 2498 | ||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -16199 | 3470 | -2347 | ||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 5236 | 4335 | 96 | ||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 6786 | 18651 | 7589 | ||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 77691 | 70905 | 52254 | ||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 70905 | 52254 | 44665 | ||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 30924 | 27250 | 20008 | ||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -9908 | -11328 | -10304 | ||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 21016 | 15922 | 9704 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 238664 | 199646 | 181053 | ||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 101243 | 83157 | 74326 | ||||||||||||||||
income-statement-row.row.gross-profit | 0 | 137421 | 116489 | 106727 | ||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-expenses | 0 | -63 | 246 | 260 | ||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 103457 | 87135 | 83732 | ||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 204700 | 170292 | 158058 | ||||||||||||||||
income-statement-row.row.interest-income | 0 | 962 | 368 | 341 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 247 | 248 | 145 | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 751 | -240 | 1139 | ||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -63 | 246 | 260 | ||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 751 | -240 | 1139 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 247 | 248 | 145 | ||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 7801 | 7673 | 6748 | ||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.operating-income | 0 | 33959 | 29349 | 22990 | ||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 34290 | 27953 | 23006 | ||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 7860 | 6803 | 6236 | ||||||||||||||||
income-statement-row.row.net-income | 0 | 26377 | 21127 | 16743 |
Często zadawane pytania
Ile wynosi Rohto Pharmaceutical Co.,Ltd. (4527.T) aktywów ogółem?
Rohto Pharmaceutical Co.,Ltd. (4527.T) całkowite aktywa to 309677000000.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to N/A.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.582.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to 74.691.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to 0.117.
Jaki jest całkowity przychód firmy?
Całkowity przychód to 0.154.
Co to jest Rohto Pharmaceutical Co.,Ltd. (4527.T) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi 26377000000.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 11693000000.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 103457000000.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 0.000.